Ignite Creation Date:
2024-05-06 @ 6:39 PM
Last Modification Date:
2024-10-26 @ 2:52 PM
Study NCT ID:
NCT05737706
Status:
RECRUITING
Last Update Posted:
2024-06-21
First Post:
2023-02-10
Brief Title:
Study of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation
Sponsor:
Mirati Therapeutics Inc
Organization:
Mirati Therapeutics Inc
Study Overview
Official Title:
A Phase 12 Multiple Expansion Cohort Trial of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation
Status:
RECRUITING
Status Verified Date:
2024-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A Phase 12 study of MRTX1133 in solid tumors harboring a KRAS G12D mutation
Detailed Description:
This first-in-human clinical trial will begin with an exploration of MRTX1133 dose and regimen As potentially viable regimens are identified Phase 1b expansion cohorts may be implemented to ensure collection of sufficient safety and PK information and early evidence of clinical activity are available to recommend Phase 2 regimens In Phase 2 separate cohorts of patients by histological diagnosis andor baseline characteristics will be evaluated for the clinical activity and efficacy of MRTX1133
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| CA246-0005 | OTHER | None | None |
| 1133-001 | OTHER | None | None |